Testing Hepatitis B Vaccine Booster Doses in Young Adults
Tests hepatitis B vaccine booster doses in young adults lacking protective antibodies against hepatitis B.
Key facts
- Who runs it
- National Taiwan University Hospital
- Where
- Taipei, TaiwanSee the site
- Trial code
- Registry title
- The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
- Status
- Recruiting
- People taking part
- 240 people, planned
- Started
- 1 Aug 2021
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- recombinant hepatitis B vaccine
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy young adults in Taiwan who have no protective hepatitis B antibodies. They will get 1-2 doses of hepatitis B vaccine.
- Age
- 20 to 36 years
- Sex
- All sexes can join.
- Disease stage
- Tested negative for hepatitis B surface antibody and surface antigen at baseline; in good health.
- Earlier treatment
- Born in Taiwan and had a full course of at least three hepatitis B vaccine doses as an infant. Never vaccinated against hepatitis B in childhood and adolescence, by questionnaire.
- Biomarker or test result
- Negative for hepatitis B surface antibody and surface antigen at baseline.
Main reasons for not taking part
- Earlier allergy to the hepatitis B vaccine or its components, such as yeast
- Vaccinated against hepatitis B during childhood and adolescence
- Positive test for hepatitis B surface antibody
- Positive test for hepatitis B surface antigen
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- The actual age at the time of admission was higher than 20 years old and birth year after 1987
- Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period
- Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
- Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
- Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
- In good health
Who cannot take part
- Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
- Those who have been vaccinated against hepatitis B during childhood and adolescence
- Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 36 years old?
Where in Taiwan
- Family Medicine, NTUHTaipei, TaiwanContact: CHYI-FENG JAN, MD, PhDTaking people
About the trial
What the trial wants to find out
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer<10 mIU/mL) need to take.
The 4 groups in the trial
- Low titer with two doses of HB VaccinesTreatment being tested
anti-HBs titer 2.5-10 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
Treatment: recombinant hepatitis B vaccine
- Low titer with one dose of HB VaccineExisting treatment, for comparison
anti-HBs titer 2.5-10 mIU/mL with one dose of HB Vaccine at Day 0
Treatment: recombinant hepatitis B vaccine
- Extremely low titer with two doses of HB VaccinesExisting treatment, for comparison
anti-HBs titer lower than 2.5 mIU/mL with two doses of HB Vaccines at Day 0 and Day 28
Treatment: recombinant hepatitis B vaccine
- Extremely low titer with one dose of HB VaccineExisting treatment, for comparison
anti-HBs titer lower than 2.5 mIU/mL with one dose of HB Vaccine at Day 0
Treatment: recombinant hepatitis B vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
- Plain-language title
- Testing Hepatitis B Vaccine Booster Doses in Young AdultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04970836, who can take part
- Record updated
- 21 October 2026